scholarly journals Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Thyroid ◽  
2010 ◽  
Vol 20 (11) ◽  
pp. 1209-1214 ◽  
Author(s):  
Theo D. Kim ◽  
Michaela Schwarz ◽  
Hendrik Nogai ◽  
Peggy Grille ◽  
Jörg Westermann ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Myeloid Leukemia ◽  
Thyroid Dysfunction ◽  
Second Generation ◽  
Kinase Inhibitors ◽  
Philadelphia Chromosome ◽  
Philadelphia Chromosome Positive

scholarly journals Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors

2020 ◽  
Vol 9 (7) ◽  
pp. 2251
Author(s):  
Valentín García-Gutiérrez ◽  
Juan Carlos Hernández-Boluda
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Myeloid Leukemia ◽  
Second Generation ◽  
Kinase Inhibitors ◽  
Treatment Options ◽  
Significant Proportion ◽  
Correct Identification ◽  
Inadequate Response

Despite the excellent overall survival (OS) of patients with chronic myeloid leukemia (CML), a significant proportion will not achieve optimal response to imatinib or second-generation tyrosine kinase inhibitors (2GTKI). For patients with inadequate response to 2GTKIs, alternative 2GTKIs or ponatinib are widely available treatment options in daily clinical practice. Treatment decisions should be guided by correct identification of the cause of treatment failure and accurate distinction between resistant from intolerant or nonadherence patients. This review aims to provide practical advice on how to select the best treatment option in each clinical scenario.

Sign in / Sign up

Export Citation Format

Share Document